Hypogonadism is the Most Common Neuroendocrine Disorder After TBI
Central hypogonadism (gonadotropic insufficiency) is the most frequently occurring neuroendocrine disorder following traumatic brain injury, affecting approximately 16-23% of male patients and 14% of female patients in the post-acute phase. 1, 2
Evidence Hierarchy and Prevalence Data
The most recent and comprehensive military cohort study (2026) with systematic tri-axis screening of 493 service members found central hypogonadism to be the predominant disorder at 6.7% of all patients (33 cases), representing 73% of all confirmed neuroendocrine dysfunction cases 1. When examining only male patients in the 1-2 year post-injury window, the prevalence reaches 19% 2.
Ranking of Neuroendocrine Disorders by Frequency:
- Gonadotropic insufficiency (hypogonadism): 16-23% in males, 14% in females 1, 2, 3
- Somatotropic insufficiency (growth hormone deficiency): 11.5-12.1% acutely, increasing to 24% in patients ≥5 years post-injury 2, 4
- Corticotropic insufficiency: 9.2% at 1-2 years, decreasing to 2.5% long-term 2
- Thyrotropic insufficiency: 2-3.3%, becoming rare long-term 1, 2
Clinical Context and Temporal Evolution
The pattern of neuroendocrine dysfunction evolves significantly over time. Gonadotropic insufficiency remains consistently prevalent throughout all phases of recovery 2, 4, while growth hormone deficiency shows a biphasic pattern—present early but increasing substantially in patients evaluated ≥5 years post-injury (24.1%) 2. This temporal evolution underscores why hypogonadism maintains its position as the most common disorder: it appears early and persists chronically.
Key Diagnostic Considerations:
- Acute phase (0-3 months): Up to 80% show gonadotropin abnormalities, though many are transient 5
- Post-acute phase (1-2 years): Hypogonadism stabilizes at 16-19% in males 2
- Chronic phase (≥5 years): Hypogonadism remains stable while GHD prevalence increases 2
Important Clinical Pitfalls
The overlap between TBI symptoms and hypogonadism symptoms creates diagnostic challenges. Fatigue, cognitive impairment, mood disturbances, and reduced exercise tolerance occur in both conditions 6, 7. This symptom overlap means hypogonadism is frequently missed unless systematic endocrine screening is performed.
The 2026 military study revealed a critical finding: confirmed neuroendocrine dysfunction (9.1%) was substantially lower than physician-diagnosed cases (54%) in earlier studies 1, 4, highlighting the importance of laboratory confirmation rather than clinical suspicion alone. The diagnostic criteria matter significantly—prevalence estimates vary from 35% (lowered basal labs only) to 55.6% (labs plus hormone replacement need) 4.
Screening Recommendations
Based on the evidence showing 25% of TBI survivors have at least one pituitary hormone deficiency 5, and that gonadotropic insufficiency is most common, screening should prioritize gonadal axis assessment first, followed by thyroid axis 1. Growth hormone screening via IGF-1 alone is insufficient—the 2026 study found only 0.2% screen-positive for GHD by IGF-1, though true prevalence remains unknown without systematic stimulation testing 1.
Screen at multiple time points: admission, 3 months, 1 year, and consider re-evaluation at 5+ years given the biphasic pattern of dysfunction 2, 5, 4. Neuroendocrine dysfunction was associated with increased time since injury and, paradoxically, fewer lifetime TBIs 1, suggesting single severe injuries may carry higher risk than repetitive mild trauma.